How Accurate Is a Benign Breast Biopsy Showing Fibrosis?

The Bottom Line: A benign biopsy result of breast fibrosis (scar-like connective tissue) is highly reassuring, provided the correct area was sampled and the radiologist formally documents that the imaging and pathology are concordant (they make logical sense together). If the result is discordant or the sample was inadequate, further evaluation is needed.

A breast biopsy that returns a benign (non-cancerous) result of breast fibrosis is generally highly accurate. However, the word “benign” on a pathology report is only one piece of the puzzle. For you to be fully reassured, your breast care team must confirm that the sample was adequate and that the finding of fibrosis plausibly explains the abnormality seen on your imaging ^[1].

When these results align well—a state known as radiologic-pathologic concordance—the risk of a missed cancer is extremely low. For context, one large study of patients with various concordant benign biopsies reported a false-negative rate of just 0.18% ^[2]. It is important to distinguish the risk of a cancer being missed in the biopsied target from the separate possibility of a new cancer developing later; routine screening still matters.

What is Breast Fibrosis?

Breast fibrosis is a benign condition where extra connective, scar-like tissue develops in the breast. It may be described on your report as “simple fibrosis,” “stromal fibrosis,” or “dense stromal fibrosis.” While fibrosis itself is completely benign, it is important to know if it was found alone or alongside other “high-risk” findings (like atypia), as this can change your management plan.

The Importance of Radiologic-Pathologic Concordance

The most critical factor in trusting a benign biopsy is radiologic-pathologic concordance. This is the formal process where your breast care team (usually the radiologist) compares the pathology report (what the cells look like under a microscope) with your imaging (mammogram, ultrasound, or MRI).

Because breast fibrosis can sometimes mimic the appearance of cancer on imaging—showing up as an irregular mass, architectural distortion, or suspicious enhancement ^[3]—it is essential that the biopsy result reasonably and adequately explains what was seen on the scan ^[4].

If the imaging looked highly suspicious (often graded as BI-RADS 4C or 5) but the biopsy only showed simple fibrosis, this is considered discordant ^[5]. A discordant result means the biopsy likely missed the true target, and the fibrosis does not explain the abnormal imaging.

Sampling Adequacy and Image Guidance

For a needle biopsy to be reliable, it must adequately sample the exact tissue in question. The radiologist’s assessment of adequacy matters more than the specific tools used, but several factors are involved:

• Image Guidance and Clip Placement: Biopsies are guided by ultrasound, mammography (stereotactic), or MRI. Placing a small marker (clip) marks the biopsy site. However, the clip alone does not guarantee the correct spot was biopsied; the team uses post-biopsy imaging to confirm the clip is in the expected location relative to the target ^[6].
• Needle Size and Type: Generally, 14-gauge core needles are commonly used and often obtain more tissue than smaller 16-gauge needles ^[7]. Vacuum-assisted biopsies pull larger volumes of tissue into the needle and can improve accuracy for certain lesions ^[8][9], though they are not automatically required for every benign biopsy.
• Tissue Volume: The pathologist must receive enough representative tissue to make a definitive diagnosis.

When Is There Concern for a False-Negative?

A false-negative occurs when a biopsy says there is no cancer, but a cancer is actually present. While very rare in fully concordant cases, a false-negative concern remains high if there is imaging-pathology discordance ^[1].

If a highly suspicious (BI-RADS 4C or 5) imaging finding yields a discordant benign biopsy, the risk of finding cancer during a follow-up surgery can be substantial. In one study of a highly selected group of patients with suspicious imaging and discordant biopsies (which included dense stromal fibrosis), 47.3% were later “upgraded” to a cancer diagnosis at surgery ^[5]. Note: This high number applies only to highly suspicious, discordant cases, not to patients with a typical, concordant fibrosis biopsy.

Additionally, your clinical symptoms matter. You should contact your breast care team promptly if you notice a new or enlarging lump, new skin or nipple retraction, bloody nipple discharge, or a new underarm lump, even after a benign biopsy ^[4]. These symptoms do not automatically mean cancer, but they do require reassessment.

Next Steps After Your Biopsy

If your biopsy result is discordant or the sample is deemed inadequate, it should be addressed promptly by your breast care team ^[1]. This usually involves:

• Repeat Biopsy: Often performed using a vacuum-assisted device or a different imaging guidance method to target the area again ^[10].
• Surgical Excision: A localized surgery to remove the entire suspicious area so the pathologist can examine the whole lesion ^[10]. (Note that excision involves surgical risks such as bleeding, infection, and scarring).
• Pathology Review: Having another specialized breast pathologist review the slides. This can identify interpretive issues but cannot fix a biopsy that missed the target.

If your results are fully concordant and adequately sampled, you should follow your radiologist’s formally documented recommendation ^[4][2]. Depending on your overall risk and the specific imaging findings, this could mean returning to routine annual screening or having a short-term targeted follow-up scan (e.g., in 6 months). Always leave your appointment with a specific, dated follow-up plan.